Alta Life Sciences

We are thrilled to announce that our partner and co-Founder, Montserrat Vendrell, is a panelist at Tech Spirit Barcelona 2024, sharing her expertise in the intersection of science, engineering, and venture capital. 🎤 Panel Title: Company Creation from an Investor Perspective: Science, Engineering, and Venture Capital 📅 Date: 11th December 2024 Montserrat brings a wealth of experience in supporting transformative biotech ventures and fostering innovation at the convergence of research and entrepreneurship. This session promises to deliver valuable insights into how investors approach company creation in deep tech fields. Don’t miss the opportunity to gain unique perspectives on translating groundbreaking science into impactful ventures. 🔗 Learn more about the panel and Tech Spirit Barcelona here: https://lnkd.in/dbdfsAqp We hope to see you there! 🚀 #TechSpiritBarcelona #VentureCapital #Biotech #DeepTech #Innovation

Peptomyc announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC patients https://shorturl.at/fqJ7N

An important moment for deepull today, as we announce the FDA granting Breakthrough Device Designation for our UllCORE Bloodstream Infection Test.   The one hour, direct-from-blood test detects 95% of sepsis-causing pathogens, as well as select genetic determinants of antimicrobial resistance.   We look forward to engaging in fruitful discussions with the FDA as we continue the development process. https://lnkd.in/dXqTaD3P   #deepull #FDA #diagnostics

Agendar consultas com o especialista certo de forma simples, usando apenas IA? Leia a nossa história de sucesso mais recente! (EN ⬇️) A Sanitas (Bupa) implementou o Mediktor para encaminhar os pacientes para os serviços apropriados, obtendo resultados impressionantes em tempo recorde. Faça o download da nossa história de sucesso e veja como o Mediktor pode otimizar os seus processos em menos de 3 minutos! Solicita del success case aquí ➡️https://lnkd.in/dyWHq74M - Schedule appointments effortlessly with the right specialist using AI alone? Check out our latest success story! Sanitas (Bupa) implemented Mediktor to direct patients to the appropriate services, yielding impressive results in record time. Download our success story to see how Mediktor can optimize your processes in less than 3 minutes! Request the success story here ➡️ https://lnkd.in/dUdRnxYN #IA #HealthTech #SaúdeDigital #Seguros

Mediktor is ISO 27001 certified! In collaboration with ADOK CERTIFICACIÓN, S.L. an international partner for this achievement of Alcumus we are proud to announce that we have obtained the world's most recognized standard for Information Security Management Systems (ISMS). Achieving ISO 27001 certification demonstrates Mediktors systematic and secure management of sensitive information, a practice we've maintained since our beginnings over 10 years ago. Congratulations to our team and everyone involved in this process! Contact us for a demo ➡️ https://lnkd.in/dScQM4kt #ISO27001 #ISOCertified

See you in Lille at #BioFIT2024! Our partner Philippe Monteyne is speaking at the 13th edition of @BioFIT Event during the session “Biotech investors’ forecast: Where will early-stage investment go in 2025?” to explore biotech investment trends from 2024, review key deals, and forecast where early-stage investments will be directed in 2025, focusing on geographical diversity and high-potential therapeutic areas. BioFIT is the place to be for early-stage deals and investment rounds in the #LifeSciences sector: let’s network, learn and explore the latest advances in our field! 📅 December 3rd and 4th, 2024, in Lille (France) 👉 To learn more about the event and the conference programme: https://lnkd.in/gJrr22P Looking forward to meeting you there!

Exciting day at the #UglyDuck24 conference! Jose Maria Fernandez and Philippe Monteyne, partners at Aliath, are attending EIF’s flagship #venturecapital conference today! The team is excited to learn and discuss the latest industry trends and future perspectives with thought leaders. Stay tuned for insights on this event! 💡 #AliathBioventures #EIFevent #Innovation #lifesciences

We are glad to announce that our colleague Montserrat Vendrell, co-founding partner of Aliath Bioventures, participated in the BNEW - Barcelona New Economy Week #BNEW2024 and shared her insights on healthcare innovation. Montserrat joined a session moderated by Santiago de Torres, Executive President of Atrys Health, with Josep Maria Campistol, director of the Hospital Clínic de Barcelona, and Manel del Castillo Rey, director of the Hospital Sant Joan de Déu Barcelona to discuss the transformative role of new technologies in healthcare. Montserrat highlighted the critical role of investors in driving innovation, particularly in disruptive technologies such as #AI, which are revolutionising diagnostics, treatments and the sustainability of healthcare systems. She stressed the importance of analysing these disruptions to understand how the market, hospitals and patients will respond. Supporting technology in healthcare is essential as its impact is far-reaching across the system. The 5th edition of BNEW was a huge success, attracting over 12,700 professionals from 106 countries and facilitating over 10,000 networking connections across seven interconnected sectors - Digital Industry, Mobility, Sustainability, Aviation, Talent, Health and Experience - the event offered a wealth of knowledge. #Innovation #Healthcare #AI #BNEW2024 #Sustainability #Investment #Technology

SPA - Società Prodotti Antibiotici and Inbiomotion sign an exclusive distribution agreement for MAF Test® in Italy SPA - Società Prodotti Antibiotici, a leading pharmaceutical company of innovative healthcare products and diagnostic tools, and Inbiomotion, proprietors of MAF Test® for identifying high risk early-stage breast cancer patients, have signed an exclusive distribution agreement to start offering the MAF Test® in Italy. The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists identify patients potentially receptive to the prevention of recurrence and who may benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated or are being treated with bisphosphonates. Thanks to this agreement, the MAF Test® could increase the survival of 8 out of 10 of the 55,000 early-stage breast cancer patients diagnosed each year in Italy. Joël Jean-Mairet, Executive Chairperson of Inbiomotion since 2012 and Executive Chairperson of Ysios Capital commented, "We are thrilled to partner with SPA - Società Prodotti Antibiotici to bring the cutting-edge MAF Test® to Italy. This collaboration represents a significant step forward in making precision medicine accessible to more patients. At Inbiomotion, our mission has always been to transform cancer treatment by providing an innovative diagnostic tool that empower both healthcare professionals and patients to make the best possible decisions. By offering a tailored approach to cancer treatment, we can significantly improve patient outcomes, reduce the likelihood of unnecessary treatments, and ultimately enhance the quality of life for those battling breast cancer. We believe that this partnership with SPA - Società Prodotti Antibiotici will play a crucial role in achieving these goals in the Italian market." # PerspectiveFromKnowledge #UncoverTheUndiscovered #CancerDiagnostics #BreastOncology #PrecisionMedicine #PatientJourney For more information: https://lnkd.in/dnerZKxZ

INBRAIN Neuroelectronics Announces World’s First Human Graphene-based Brain Computer Interface Procedure INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company pioneering graphene-based neural technologies, announced today the world’s first human procedure of its cortical interface in a patient undergoing brain tumor resection. INBRAIN’s BCI technology was able to differentiate between healthy and cancerous brain tissue with micrometer-scale precision. Read more: https://lnkd.in/dbbddWGZ #INBRAINNeuroelectronics #Graphene INBRAIN Neuroelectronics #braincomputer #braintumor #cancerous #BCItechnology